Safety of Administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19
Vaccine in Youths and Young Adults with a History of Acute Lymphoblastic
Leukaemia and Allergy to PEG-Asparaginase
Abstract
Vaccination is a critical tool in the prevention of COVID-19 infection
for individuals and for communities. The mRNA vaccines contain
polyethylene glycol (PEG) as a stabilizer. Currently in North America
only the BNT162b2 (Pfizer-BioNTech) mRNA vaccine is approved individuals
12 to 17 years of age. Most patients treated with contemporary regimens
for acute lymphoblastic leukemia receive Peg-asparaginase and 10-30%
will develop allergic reactions. Optimizing access and safety for
vaccine administration for these patients critical. This report
describes a process developed to support COVID vaccination in a cohort
of adolescents and young adults with a history of PEG-asparaginase
allergy.